Platensimycin is a selective FabF inhibitor with potent antibiotic properties

By Jun Wang, S. Soisson, K. Young, W. Shoop, S. Kodali, Andrew M. Galgoci, R. Painter, G. Parthasarathy, Y. S. Tang, R. Cummings and 27 more. Nature, 2006

737 citations recorded by the source corpus.

Subfields: Molecular Biology, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/632cb397f532dd892626b3c58d5f5f1371401e43

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Xian-Zhi Li
2. H. Nikaido
3. T. Foster

In Molecular Medicine

1. Xian-Zhi Li
2. H. Nikaido
3. T. Foster

In Pharmacology

1. H. Nikaido
2. Xian-Zhi Li
3. T. Foster
4. R. Meyer
5. T. Mygind
6. M. Hyldgaard

Citations in the corpus

• Efflux-Mediated Drug Resistance in Bacteria: an Update (2009, background): “, the oxazolidinone linezolid, the lipopeptide daptomycin and a ketolide connected to a polar aromatic residue, platensimycin.([726,727]) Thus, development of novel antibacterial drugs has been challenged by the rapid emergence of bacterial resistance, especially MDR, as well as by the unwillingness”
• Antibiotic resistance in Staphylococcus aureus. Current status and future prospects (2017, background): “The antibiotic platensimycin inhibits FabF but it is unclear if it or other inhibitors of this enzyme will be developed further and progress towards clinical trials (Wang et al. 2006).”
• Essential Oils in Food Preservation: Mode of Action, Synergies, and Interactions with Food Matrix Components (2012, background): “…whereas nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, and computer modeling help identify key residues involved in the molecular interactions between target and the antimicrobial (Wang et al., 2006; Domadia et al., 2007; Liu et al., 2010; Schneider et al., 2010).”